BirchBioMed (@BirchBioMed) header
BirchBioMed (@BirchBioMed) profile picture

BirchBioMed

@BirchBioMed

BirchBioMed Inc. is exclusively licenced by the University of British Columbia to develop anti-scarring drugs and autoimmune therapies based on FS2

 Toronto, Vancouver, New York
birchbiomed.com
Joined August 2016
  • Tweets11
  • Following18
  • Followers43
1Media
Photo by BirchBioMed (@BirchBioMed)
Sensus Healthcare Launches Collaboration with BirchBioMed sensushealthcare.com/press-r…
1
BirchBioMed retweeted
UBC UILO (@techtransfer) profile picture
UBC UILO@techtransfer2 Sep 2016
Times Square spotlight shines on @UBC spin-off company @birchbiomed's anti-scarring drug developed at @VCHResearch
Image from UBC UILO (@techtransfer)
7
4
BirchBioMed in New York City! Dr. Ghahary and Dr. Hartwell on the sign in Times Square #clinicaltrials #AntiScarring
Image from BirchBioMed (@BirchBioMed)
1
3
1
BirchBioMed retweeted
CNWBiotech (@CNWBiotech) profile picture
CNWBiotech@CNWBiotech29 Aug 2016
.@BirchBioMed announces completion of #clinicaltrial for ground-breaking anti-scarring #drug dld.bz/eRwCs
Image from CNWBiotech (@CNWBiotech)
1
3
.@BirchBioMed announces completion of #clinicaltrial for ground-breaking anti-scarring #drug dld.bz/eRwCs
Image from CNWHealthcare (@CNWHealthcare)
1
1
BirchBioMed retweeted
CNWNews (@CNWNews) profile picture
CNWNews@CNWNews29 Aug 2016
.@BirchBioMed announces completion of #clinicaltrial for ground-breaking anti-scarring #drug dld.bz/eRwCs
Image from CNWNews (@CNWNews)
1
2
BirchBioMed announces completion of clinical trial for ground-breaking anti-scarring drug lnkd.in/ebsvUtx
BirchBioMed's ground-breaking therapeutics in the news @BirchBioMed #scarring #autoimmune #biomedical teapawt.net/BirchBioMed/status/769…
BirchBioMed (@BirchBioMed) profile pictureBirchBioMed@BirchBioMed26 Aug 2016
BirchBioMed announces completion of clinical trial for ground-breaking anti-scarring drug bit.ly/2boNZmu
2
3
BirchBioMed announces completion of clinical trial for ground-breaking anti-scarring drug bit.ly/2boNZmu
1
1
1
Load more